Evidence map›Paper›PMID 40887501›Full record

ReviewExperimental & molecular medicine2025

Th17 cell pathogenicity in autoimmune disease.

Eunchong Park, Maria Ciofani

Abstract readReview
In one paragraph

Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Microparticles synthesized from itaconate polyesters enable metabolite delivery and elicit immunoregulatory outcomes.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Alteration of small intestinal microbiota in diet-induced steatohepatitis mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eunchong ParkBioscience Immunology, Research and Early Development, Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0001-8018-664X
Maria CiofaniDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, USA. maria.ciofani@duke.edu.ORCID http://orcid.org/0000-0001-6472-5260

Funding

The role of AP-1 family transcription factor networks in regulating TH17 cell effector identityR01GM115474 · NIGMS · DUKE UNIVERSITY · PI CIOFANI, MARIA · 2016 to 2024
$3.2M
Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosisR01AI156186 · NIAID · DUKE UNIVERSITY · PI CIOFANI, MARIA · 2021 to 2025
$3.1M
NIAID NIH HHS R01 AI156186NIGMS NIH HHS R01 GM115474U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI156186U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM115474
6 · The paper itself

Abstract

T helper 17 (Th17) cells have been implicated in numerous inflammatory autoimmune diseases. Clinical benefits from targeting Th17 cell-related cytokines, such as IL-17 and IL-23, highlight how knowledge of Th17 cell development and effector function can be translated into treatments for inflammatory disease. Here we discuss the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease and psoriasis, with emphasis on the cytokines, transcriptional regulators and metabolites that influence Th17 cell differentiation and pathogenicity. Moreover, we address how intestinal environments and physiological responses affect Th17 cells in autoimmune diseases. We also examine current and emerging therapeutic strategies aimed at regulating Th17 cell-driven inflammation to mitigate autoimmune diseases.

Indexed as

Autoimmune DiseasesTh17 CellsAnimalsCell DifferentiationCytokinesDisease SusceptibilityHumansCytokines

Identifiers

PMID40887501
PMCPMC12508148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.